Order by treating provider; interpretation by board‑certified sleep medicine physician

HSAT and/or PSG orders must be placed by a treating medical provider and interpretation must be by a board‑certified sleep medicine physician or a provider overseen by one. A reasonable attempt to obtain prior sleep testing results must be documented before requesting repeat testing.

• Treating medical provider = MD, DO, NP, Clinical Nurse Specialist, or PA
• Document attempts to obtain prior study (contact prior facility/provider or DME; ask patient for copy)

In‑lab full‑night PAP titration required when bilevel PAP is requested for listed indications

An in‑lab full‑night PAP titration is medically necessary when bilevel PAP (HCPCS E0470 or E0471) is specifically requested for listed conditions — e.g., after unsuccessful APAP/CPAP trial or for diagnoses such as central sleep apnea, treatment‑emergent CSA, neuromuscular/restrictive thoracic disease, severe COPD (PaCO2 ≥52 mmHg), obesity hypoventilation syndrome, or other hypoventilation disorders.

• Bilevel requested because CPAP/APAP ineffective or not tolerated
• Objective physiologic thresholds (e.g., PaCO2 ≥52 mmHg for severe COPD; OHS PCO2 criteria) apply

Inclusion of codes does not imply PA or management requirement

The presence of a code in the guideline coding tables does not in itself mean that the code is managed or requires prior authorization; refer to the applicable health plan for plan‑specific management and prior authorization details.

• Prior authorization of a listed code is not a guarantee of payment
• Check the member's Certificate of Coverage / Evidence of Coverage for plan specifics

Prior authorization expected for in‑lab PSG (including pediatrics) when indications present

Prior authorization is expected when in‑lab polysomnography (full‑night, split‑night, or in‑lab PAP titration) is requested because clinical evaluation indicates sleep‑disordered breathing and one or more listed indications or comorbid conditions are documented; pediatric in‑lab PSG uses CPT 95782/95783.

• Document at least one PSG indication or comorbidity per guideline (e.g., BMI thresholds, pulmonary/cardiac/neurologic conditions)
• Use CPT 95782/95783 for pediatric in‑lab PSG/titration

Authorization conditions for split‑night PSG and PSG+MSLT

Split‑night PSG is appropriate only when diagnostic AHI ≥15/hour during ≥2 hours of diagnostic recording and at least 3 hours remain available for PAP titration; PSG immediately followed by MSLT must meet documented MSLT prerequisites and follow an attended PSG on adequate sleep/treatment settings.

• Split‑night: AHI ≥15/hr during ≥2 hours and ≥3 hours available for titration
• MSLT: must immediately follow an attended PSG and meet duration/sleep sufficiency and exclusion criteria

Prior authorization may be required for HGNS‑related pre‑ and post‑implant PSGs

Pre‑implant and post‑implant in‑lab PSGs for hypoglossal nerve stimulator evaluation and device optimization are medically necessary under the guideline's specified criteria and may require prior authorization when requested for HGNS evaluation or fine‑tuning.

• Pre‑implant: HSAT and PAP trial recommended if no prior testing; in‑lab pre‑implant PSG required when pre‑specified criteria (BMI ≤40, AHI/REI ≤100, PAP intolerance after 3‑month trial, etc.) are met
• Post‑implant: in‑lab PSG ≥2 months post‑implant for parameter fine‑tuning; repeat PSG if clinical response insufficient or prior test inadequate

Prior authorization for TPNS‑related PSGs (pre‑ and post‑implant)

Polysomnography is medically necessary prior to TPNS implantation when all listed pre‑implant eligibility criteria are met (e.g., age ≥18, central AHI ≥15/hr, CSA not primarily opioid‑related, absence of transient causes, and documentation of prior PAP contraindication/failure/intolerance after a ≥3‑month trial); such PSGs and post‑implant programming PSGs may require prior authorization.

• Pre‑implant: document central AHI ≥15/hr and prior ≥3‑month PAP trial failure/intolerance
• Post‑implant: PSG with device interrogation/programming can be performed ≥2 months after implantation for optimization

PSG for TPNS evaluation and post‑implant programming

Polysomnography with phrenic nerve stimulator interrogation/programming may be performed at least 2 months post‑implant for device optimization; repeat in‑lab PSG is medically necessary if clinical response is insufficient or prior test was inadequate.

• Initial post‑implant PSG timing: ≥2 months after implantation
• Retest triggers: insufficient clinical response or inadequate prior test (report required)

Do not rely on repeat sleep testing solely to continue/resume Zepbound

A repeat sleep study should not be ordered solely to continue or resume Zepbound (tirzepatide); prior authorization/justification must not rely on repeat testing alone and reassessment should follow the guideline's repeat‑testing rules.

• For Zepbound continuation/resumption, do not use repeat diagnostic testing as the sole justification
• Follow SL‑2.6 Repeat sleep testing guidance for reassessment while on or after Zepbound

PAP device and supply codes listed — inclusion does not imply PA

Treatment device and supply HCPCS/CPT codes (PAP devices, interfaces, humidifiers, monitoring, and related supplies) are listed in the guideline; inclusion of these codes does not itself indicate a prior authorization requirement — check the member's plan.

• Examples include E0601, E0470, E0471, E0472, E0561, E0562, A7027–A7046, A9279, and CPT 94660
• Refer to the health plan for plan‑specific prior authorization rules

Prior authorization required for E0601 and E0470/E0471 device initiation/purchase

Prior authorization is required for initiation/purchase of HCPCS E0601 (APAP/CPAP) and HCPCS E0470/E0471 (Bi‑level PAP) devices; orders must follow a documented clinical evaluation and be based on qualified testing.

• E0601 initiation requires positive diagnosis (HSAT or PSG) and order by treating provider after clinical evaluation
• Authorization for purchase requires documentation of compliance/reevaluation and plan‑specific requirements

PA for PAP/ASV requires documented qualifying condition and objective testing

Prior authorization for PAP devices including ASV (E0471) requires documentation of one of the qualifying medical conditions and supporting objective testing/results as specified in the guideline (e.g., CSA criteria, neuromuscular disease with physiologic data, severe COPD with PaCO2 thresholds).

• Document the qualifying diagnosis (central sleep apnea, treatment‑emergent CSA, neuromuscular disease, severe COPD, OHS, or other hypoventilation)
• Include objective physiologic data (ABG/PaCO2, EtPCO2/TcPCO2, vital capacity, nocturnal oximetry) as required

Inclusion of a code does not by itself indicate PA is required

Again, inclusion of a code in the guideline's coding tables does not by itself mean prior authorization is required; verify plan‑specific management and prior authorization requirements with the applicable health plan.

• Prior authorization determinations depend on the member's benefit plan
• Listing a code in the document does not guarantee coverage or payment

CPT 94799 / HCPCS E1399 not approvable for routine PAP equipment/supplies

Use of nonspecific DME codes (CPT 94799 or HCPCS E1399) for routine PAP machines, parts, or supplies is generally not approvable; E1399 may be approved only for specific items (e.g., PAP oxygen bleed‑in adapter) or specified repair parts when the DME supplier documents needed replacements.

• Do not submit CPT 94799 or E1399 for routine PAP equipment/supplies when specific HCPCS codes exist
• E1399 may be approved for limited items or repair parts with supplier justification

Multiple CMS LCDs/LCA identifiers cited — confirm LCD‑based coverage rules

The policy cites multiple CMS Local Coverage Determinations and LCA identifiers (e.g., L38276, L33718, L33800, L35050) — device and sleep‑study related services may be subject to LCD‑based coverage or prior authorization rules; confirm applicable LCD requirements.

• Check cited LCDs (Hypoglossal Nerve Stimulation, Respiratory Assist Devices, Outpatient Sleep Studies, etc.) for coverage specifics
• Noncompliance with an applicable LCD may affect coverage

Attach relevant FDA PMA/SSED or manufacturer documents for device prior authorizations

FDA PMA and SSED documents for implantable devices (Inspire UAS, Genio® System 2.1, aura6000®, remede®) are cited as supporting regulatory evidence; attach relevant PMA/SSED documents when submitting device‑related prior authorization requests as appropriate.

• Attach manufacturer or FDA PMA/SSED documents for HGNS/TPNS/other implantable device requests when relevant
• Manufacturer manuals and billing guides are also cited as supporting documentation

Documented APAP trial (≥30 days) required before in‑lab titration for unsuccessful APAP

Documented APAP (auto‑PAP) trial of at least 30 days is required before in‑lab PAP titration when OSA persists; acceptable failure evidence includes APAP download showing AHI ≥5/hr with ongoing symptoms, APAP use ≥4 hours/night on 70% of nights with continued symptoms, or APAP intolerance despite interventions.

• APAP trial duration: ≥30 days
• Acceptable failure criteria: AHI ≥5/hr on machine download with symptoms OR adherence ≥4 hrs/night on 70% nights with persistent symptoms OR documented intolerance despite DME/provider interventions

Acceptable documentation for APAP trial failure

APAP therapy trial documentation must include at least a 30‑day trial and one of: APAP machine download with AHI ≥5/hr plus ongoing OSA symptoms; APAP usage ≥4 hours/night on 70% of nights with persistent symptoms; or documented APAP intolerance despite mask fittings, alternative masks, pressure adjustments, or desensitization.

• Upload APAP machine download and symptom documentation when claiming APAP failure
• Document interventions attempted to address intolerance (mask refitting, education, pressure changes)

In‑lab titration indicated when APAP trial (≥30 days) fails per defined metrics

A titration study is medically necessary if an APAP trial of at least 30 days has failed per the guideline metrics (machine download AHI ≥5 with symptoms; or APAP use ≥4 hours/night on 70% of nights with persistent symptoms) or if APAP intolerance persists despite interventions.

• Confirm APAP trial length and provide machine download or adherence data
• If split‑night was attempted but not completed, follow guidance on whether a second‑night titration or at‑home APAP treatment is appropriate

When split‑night not completed, choose second‑night titration vs immediate at‑home APAP per guidelines

If a split‑night study cannot be completed, the next step is either a second‑night in‑lab full‑night PAP titration or initiation of immediate at‑home APAP (E0601) per the general guidelines; decision depends on indications, comorbidities, and prior testing.

• Consider patient comorbidities and prior test adequacy when choosing second‑night titration versus immediate at‑home APAP
• Follow At‑home vs In‑lab testing guidance (SL‑1.0) for selection

HSAT and PAP trial recommended before facility HGNS testing

For HGNS evaluation, individuals without prior testing should undergo HSAT (if appropriate) and a PAP trial before consideration of in‑lab testing for implantation; evaluations should be performed by or in consultation with a board‑eligible/certified sleep medicine physician.

• If no prior testing, perform HSAT and PAP trial before facility testing for HGNS candidacy
• Document specialist involvement (board‑eligible/certified sleep physician) for pre‑implant evaluation

Document ≥3‑month PAP trial (or contraindication) before TPNS consideration

Documentation for TPNS pre‑implantation must show prior PAP contraindication, failure, or intolerance after a minimum three‑month trial (mask fittings, alternative masks, pressure changes, desensitization documented); oxygen must be contraindicated/ineffective or not tolerated.

• Minimum PAP trial: 3 months with documented interventions
• Document supplemental oxygen contraindication/ineffectiveness or intolerance when claimed

Recommend comprehensive lifestyle weight‑loss therapy before pharmacotherapy

Patients with overweight or obesity should first receive comprehensive lifestyle intervention (diet, exercise, behavioral counseling) before considering anti‑obesity pharmacotherapy, consistent with ATS/AACE/ACE recommendations referenced in the guideline.

• Lifestyle intervention goal: weight‑loss program before pharmacotherapy evaluation
• Anti‑obesity pharmacotherapy considered when lifestyle measures insufficient per guideline recommendations

CPAP medically necessary in children after PSG‑confirmed OSA if surgery unsuccessful or inappropriate

In pediatrics, CPAP is medically necessary when obstructive sleep apnea is established by PSG and adenotonsillectomy was unsuccessful or is inappropriate, or definitive surgery must await dental/facial development.

• PSG‑documented OSA required
• Document adenotonsillectomy failure or inappropriateness when claiming CPAP

Trial of CPAP/APAP required and proven ineffective before Bi‑level PAP for OSA

For OSA, CPAP/APAP (E0601) should be tried and proven ineffective or not tolerated before initiating Bi‑level PAP (E0470) for OSA indications; document the trial and interventions attempted.

• Document CPAP/APAP trial and reasons for failure (pressure discomfort, intolerance) before requesting bilevel for OSA
• Include evidence of attempted optimization (mask refitting, education, pressure adjustments)

Consider ASV only after CPAP proven ineffective for specified central apnea indications

ASV may be considered after CPAP has been shown ineffective for certain central apnea indications; prior CPAP/APAP/bi‑level attempts and relevant objective testing must be documented as specified in ASV guidance.

• Document prior mask‑based therapy attempts and objective testing meeting CSA criteria
• Discuss benefits/risks and plan for follow‑up when ordering ASV in HFrEF

Oral appliance requires documented 1‑month PAP trial (unless contraindicated) or documented intolerance

Coverage of a custom oral appliance requires documentation of intolerance or lack of benefit after a minimum one‑month trial of PAP unless PAP is contraindicated or the patient prefers an alternative; appliance orders must follow a face‑to‑face visit and review of sleep study results.

• One‑month PAP trial required (documented) unless contraindicated
• Order must be placed by treating medical provider after face‑to‑face visit; qualified dentist provides custom device

No additional step‑therapy requirements specified in reference sections

No additional step‑therapy requirements are specified in the referenced sections of the guideline beyond the therapy trials and sequencing already detailed (APAP before titration, CPAP before bilevel for OSA, PAP trials before implantable therapies, etc.).

• Follow the guideline's specific step‑therapy rules for APAP, CPAP, and device‑related therapies
• Check plan‑specific policies for any additional step‑therapy requirements

Comprehensive clinical evaluation required before sleep testing

A current comprehensive clinical evaluation (face‑to‑face or telehealth) including sleep symptoms, physical exam (cardiopulmonary exam, obesity, neck circumference, oropharyngeal exam) and relevant diagnostics/labs (ABG or serum bicarbonate within one year) is required prior to testing.

• Include comprehensive sleep history, physical exam, and relevant prior diagnostics in documentation
• ABG or serum bicarbonate within one year when applicable

Include clinical evaluation and prior test reports when available

Clinical documentation submitted with testing or device requests must include the evaluation supporting concern for OSA or other sleep‑disordered breathing, and prior HSAT/PSG reports when relevant (to demonstrate non‑diagnostic or technically inadequate studies).

• Attach prior HSAT/PSG reports when claiming prior non‑diagnostic or technically inadequate testing
• Document signs/symptoms and relevant comorbidities to justify in‑lab testing when indicated

Provide full clinical description when requesting titration or parasomnia diagnostics

When requesting titration or certain diagnostics (e.g., complicated parasomnias), include a complete description, assessment, and discussion of signs and symptomatology to support medical necessity.

• For parasomnias, describe dream‑enacting behaviors, injury risk, or concern for nocturnal seizures
• Provide narrative assessment linking symptoms to the requested in‑lab study

HSAT device must meet minimum technical features (FDA clearance, oximetry, raw data, REI calculation)

HSAT devices must meet minimum technical features — FDA approval/clearance for SDB diagnosis, unique unit identifier, capability to record oximetry and heart rate, raw data display for review, and ability to calculate an REI (or estimated sleep time for PAT devices).

• Document device model/unique identifier and FDA clearance when submitting HSAT‑based testing
• Ensure raw data are available for manual scoring or review

Use CPT 95782/95783 for pediatric PSG and submit supporting prior test/APAP data

For pediatric in‑lab PSG requests, use CPT 95782/95783 as appropriate and include prior HSAT/PSG reports when applicable to demonstrate prior non‑diagnostic HSAT or unsuccessful APAP trials.

• 95782 = pediatric full‑night diagnostic PSG; 95783 = pediatric in‑lab PAP titration
• Attach prior testing reports and APAP download/adherence data when relevant

Provide detailed clinical description for parasomnias or suspected RBD

When requesting in‑lab PSG for complicated parasomnias or suspected REM behavior disorder, provide a complete description, assessment, and discussion of the dream‑enacting or injurious behaviors and any concern for nocturnal seizures.

• Describe specific behaviors, timing, severity, and safety concerns
• Note whether standard EEG was inconclusive when differentiating seizure vs parasomnia

Document 3+ months of daytime sleepiness and sufficient sleep before PSG+MSLT

For MSLT requests, document recurrent daytime naps or lapses into sleep for at least 3 months, associated symptoms (e.g., cataplexy), exclusion of other causes of sleepiness, and demonstration of sufficient prior sleep; MSLT must immediately follow an attended PSG.

• Duration requirement: ≥3 months of recurrent daytime sleepiness
• Confirm sufficient sleep prior to PSG per age‑based hours; MSLT follows PSG directly

Submit prior sleep study reports and PAP device download data when relevant

When relevant, submit prior medically necessary sleep test reports and PAP device download data (adherence, AHI on device) to support requests for repeat testing, titration, replacement, or device upgrades.

• Include PAP download showing usage and AHI when claiming APAP/CPAP failure or requesting replacement
• Document efforts to obtain prior reports if original report unavailable

HGNS evaluation must involve board‑eligible/certified sleep medicine physician

HGNS pre‑implant evaluations should be performed by or in consultation with a board‑eligible or board‑certified sleep medicine physician; document specialist involvement in the submission.

• Note the evaluating clinician's certification status and any consultative involvement
• Attach evaluation notes that document PAP trial history and candidacy criteria

Prior sleep study report required to justify repeat testing

When prior sleep testing exists and repeat testing is requested, include the prior sleep study report to determine medical necessity; document symptom, weight, medication, neurologic, or cardiovascular changes when using those as justification for repeat testing.

• Prior report required to justify repeat HSAT or PSG
• Document specific clinical changes (≥10% weight change, new/worsening symptoms, med changes) supporting repeat testing

TPNS evaluation requires sleep medicine specialist involvement and detailed prior study/PAP documentation

TPNS evaluation must be performed by a board‑eligible/certified sleep medicine physician or in consultation with one; documentation must include prior CSA diagnosis details (date, central AHI) and prior PAP trial information.

• Include prior study central AHI and dates
• Document prior PAP trial duration, intolerance/failure, and oxygen contraindication if applicable

Pediatric PSG requests must document age, symptoms, and at least one objective finding

For pediatric in‑lab PSG requests, document the child's age (≤17 years), presenting symptoms/signs (e.g., snoring, witnessed apnea, daytime sleepiness), and at least one objective related finding (e.g., tonsillar hypertrophy, failure to thrive) linking concern to OSA; provide reasons for split‑night testing if requested.

• Age documentation (≤17) required
• List specific presenting symptoms and objective findings linking to OSA

Documentation must support listed symptoms or clinical circumstances for testing/titration

Documentation submitted for any testing, titration, or device request must support one or more listed symptoms or specific clinical circumstances in the guideline (e.g., snoring, witnessed apnea, growth impairment, Down syndrome screening).

• Cite the guideline‑listed symptom(s) or circumstance(s) that justify the requested service
• For split‑night in pediatrics, provide reason(s) for split‑night approach

DME evaluation required and warranty status documented for replacement claims

For replacement device claims, include documentation that the DME supplier physically evaluated the device and determined it cannot be repaired; failure to provide DME evaluation or if the device remains under warranty risks denial.

• DME supplier physical evaluation report required
• Confirm device is no longer covered under warranty

PAP devices and supplies must be ordered by a treating medical provider

Orders for PAP devices and supplies can only be placed by a treating medical provider (licensed MD, DO, NP, Clinical Nurse Specialist, or PA); ensure the order originates from an eligible provider.

• Non‑prescribers or administrative staff cannot place orders independently
• Include treating provider credentials on the order

Document PAP usage ≥4 hrs/night on 70% nights over 30 days and clinical reevaluation

To establish PAP usage and eligibility for continuation or replacement, document device usage of ≥4 hours per night on 70% of nights during a consecutive 30‑day period; failure to document this adherence or lack of a clinical reevaluation within 3 months may result in denial.

• Compliance metric: ≥4 hrs/night on 70% of nights over 30 consecutive days
• Clinical reevaluation within first 3 months required for continued coverage

Replacement denied if device under warranty or not evaluated by DME

Replacement requests may be denied if the device remains under warranty or the DME supplier has not determined it cannot be repaired; include warranty documentation and DME repair evaluation to avoid denial.

• Provide copy of warranty status and DME repair assessment
• If device repairable, replacement request may be denied